# Clinical Trials Data EGFR - Document 123

# Nimotuzumab in Combination With Chemoradiation for Esophageal Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT00950417

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Informed consent form signed before performing any of the study's specific procedures.\n\* ECOG performance status 0-2.\n\* Age \\> 18 and \\< 75.\n\* Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, greater than or equal to 1 cm (longest diameter) by spiral computed tomography (CT) scan and MRI or greater than or equal to 2 cm by other ordinary radiographic technique.\n\* Histologically confirmed diagnosis of locally advanced esophageal.\n\* Life expectancy of more than 3 months.\n\* Use of an effective contraceptive method for patients of both sexes when there is a risk of conception and/or pregnancy.\n\* No serious blood producing,abnormal function of heart,lung, liver, or kidney or immuno-deficiency\n\* Neutrophils \u22653\u00d7109/L, platelet count\u2265100\u00d7109/L and haemoglobin\u22659g/dL ,Creatinine \u2264 1.5 x NUL\n\nExclusion Criteria:\n\n\* Previous radiotherapy or chemotherapy\n\* Pregnant or breast-feeding women\n\* Drug abuse, unhealthy drug/alcohol addiction,or virus (HIV) infection\n\* Evidence of distant metastasis\n\* Participation in other clinical trials\n\* Patients with aphthosis, complete obstruction, fistula or deep peptic ulcer in the esophagus, or haematemesis\n\* Uncontrolled psychiatric disease or seizure\n\* Patients not fit for the clinical trial judged by the investigators",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, there is no mention of excluding patients with an EGFR gene mutation. The inclusion and exclusion criteria focus on other aspects such as the patient's health status, previous treatments, specific conditions related to the esophagus, and other health and demographic factors. Therefore, having an EGFR gene mutation does not automatically disqualify a patient from participating in this trial, as per the provided criteria.  
  
However, it's always advisable for a potential participant or their healthcare provider to discuss their specific situation with the trial investigators to ensure there are no additional considerations not explicitly outlined in the criteria provided.